Optimizing risk factors to guide COST‐effective use of palivizumab in KOREAN infants
Adoption of the IRST in Korea would provide greater protection of the most vulnerable infants born 32-35 wGA against RSVH whilst improving cost-effectiveness.
Authors
- Ji‐Man Kang (ORCID: https://orcid.org/0000-0002-0678-4964)
- Bosco A Paes (ORCID: https://orcid.org/0000-0002-3308-2706)
- Yun Sil Chang (ORCID: https://orcid.org/0000-0001-9201-2938)
- Hyeon‐Jong Yang (ORCID: https://orcid.org/0000-0002-7287-4300)
- Jean‐Éric Tarride (ORCID: https://orcid.org/0000-0003-2913-7580)
- John Fullarton (ORCID: https://orcid.org/0000-0001-9429-5994)
- Ian Keary
- Xavier Carbonell‐Estrany (ORCID: https://orcid.org/0000-0002-4453-3891)
- Barry Rodgers‐Gray (ORCID: https://orcid.org/0000-0003-0954-5587)
Institutions
- Yonsei University (KR)
- Soonchunhyang University Hospital Seoul (KR)
- Samsung Medical Center (KR)
- Hospital Clínic de Barcelona (ES)
- St. Joseph’s Healthcare Hamilton (CA)
- Sungkyunkwan University (KR)
- McMaster University (CA)
Publication Details
- Journal
- Pediatrics International
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1111/ped.70021
- Citations
- 1
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- AstraZeneca